Bettina Stubinski - Auris Medical Chief Medical Officer

Executive

Dr. Bettina Mirella Stubinski serves as Chief Medical Officer of Auris Medical Holding Ltd., since September 2013. She previously spent nine years with Merck Serono, Geneva, her last position there being Head of Global Clinical Development Multiple Sclerosis. Prior to Serono she was employed with Novartis Consumer Health, and previous to that led the Clinical Research department of Berlin Chemie, a division of the Menarini Group, which she joined in 1996 since 2013.
Age 48
Tenure 11 years
Professional MarksMBA
Phone441 295 5950
Webhttp://www.aurismedical.com
Stubinski holds an M.D. with specialization in Clinical Neurophysiology from the Medical Faculty of the University of Genova, Italy, and started her career as a practicing Neurologist. In 2014 Dr. Stubinski obtained an M.B.A. at MIT’s Sloan School of Management.

Auris Medical Management Efficiency

The company has return on total asset (ROA) of (21.99) % which means that it has lost $21.99 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (71.91) %, meaning that it created substantial loss on money invested by shareholders. Auris Medical's management efficiency ratios could be used to measure how well Auris Medical manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 523.92 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Auris Medical Holding has a current ratio of 3.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Auris Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Auris Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Auris Medical Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Auris to invest in growth at high rates of return. When we think about Auris Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Steven HopkinsBeyond Inc
N/A
Allan ChurchmackArhaus Inc
N/A
Alan HellawellSea
N/A
Yanjun WangSea
38
Emily EpsteinCoupang LLC
45
Carter LeeBeyond Inc
54
Pranam KolariCoupang LLC
N/A
Steven OBrienCDW Corp
N/A
Tushon RobinsonBeyond Inc
53
Eric NickleBeyond Inc
59
Judy BalogLB Foster
N/A
Dorothy AblesSea
57
Aletha NoonanCDW Corp
N/A
Sean CPALB Foster
51
Adrianne LeeBeyond Inc
46
James BogdanLB Foster
N/A
Chandra HoltBeyond Inc
42
Jake FuellhartLB Foster
N/A
Peter JonesLB Foster
56
Fredy IrizarryBeyond Inc
N/A
Roni CappadonnaSea
N/A
Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda. Auris Medical operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. Auris Medical Holding (EARS) is traded on NASDAQ Exchange in USA and employs 8 people.

Management Performance

Auris Medical Holding Leadership Team

Elected by the shareholders, the Auris Medical's board of directors comprises two types of representatives: Auris Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Auris. The board's role is to monitor Auris Medical's management team and ensure that shareholders' interests are well served. Auris Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Auris Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Cindy McGee, Head of Investor Relations and Corporate Communications
Hernan Levett, CFO
James Healy, Non-Executive Independent Vice Chairman of the Board
Bettina Stubinski, Chief Medical Officer
Thomas Meyer, Founder, Chairman, CEO and Managing Director
Calvin Roberts, Non-Executive Independent Director
Wolfgang Arnold, Board Member
Oliver Kubli, Board Member
Thomas Jung, Chief Development Officer
Andrea Braun, Head of Regulatory and Quality Affairs
Mats Blom, Director
Antoine Papiernik, Non-Executive Independent Director
Anne Zoller, General Counsel
Berndt Modig, Non-Executive Independent Director
Sven Zimmermann, CFO
Armando Anido, Non-Executive Independent Director
Alain Munoz, Director

Auris Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Auris Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Auris Medical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Auris Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Auris Medical will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Consideration for investing in Auris Stock

If you are still planning to invest in Auris Medical Holding check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Auris Medical's history and understand the potential risks before investing.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk